Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aratana Theraptcs (PETX)

Aratana Theraptcs (PETX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,417
  • Shares Outstanding, K 48,969
  • Annual Sales, $ 35,410 K
  • Annual Income, $ -14,720 K
  • 60-Month Beta 1.40
  • Price/Sales 7.00
  • Price/Cash Flow N/A
  • Price/Book 2.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.73 +5.07%
on 06/18/19
5.30 -6.23%
on 06/26/19
+0.23 (+4.85%)
since 06/17/19
3-Month
3.35 +48.36%
on 04/22/19
5.30 -6.23%
on 06/26/19
+1.44 (+40.79%)
since 04/17/19
52-Week
3.30 +50.61%
on 03/13/19
7.16 -30.59%
on 11/08/18
+0.55 (+12.44%)
since 07/17/18

Most Recent Stories

More News
Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for...

PETX : 4.96 (+0.61%)
Rigrodsky & Long, P.A. Files Class Action Suit Against Aratana Therapeutics, Inc.

Rigrodsky & Long, P.A.:

PETX : 4.96 (+0.61%)
Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for...

PETX : 4.96 (+0.61%)
AMBR, PETX Shareholder Class Actions: Halper Sadeh LLP Announces Shareholder Class Action Lawsuits Against Amber Road, Inc. and Aratana Therapeutics, Inc. - AMBR, PETX

Halper Sadeh LLP, a global investor rights law firm, announces the filing of class action lawsuits against Amber Road, Inc. (NYSE: AMBR) and Aratana Therapeutics, Inc. (NASDAQ: PETX). The lawsuits seek...

AMBR : 13.05 (-0.08%)
PETX : 4.96 (+0.61%)
Rigrodsky & Long, P.A. Files Class Action Suit Against Aratana Therapeutics, Inc.

Rigrodsky & Long, P.A.:

PETX : 4.96 (+0.61%)
PETX, ADSW, AQ Shareholder Alert: Halper Sadeh LLP Reminds Investors of Class Action Lawsuits Filed Against Aratana Therapeutics, Inc., Advanced Disposal Services, Inc., and Aquantia Corp. - PETX, ADSW, AQ

Halper Sadeh LLP, a global investor rights law firm, announces that class action lawsuits were filed against Aratana Therapeutics, Inc. (NASDAQ: PETX), Advanced Disposal Services, Inc. (NYSE: ADSW), and...

AQ : 13.17 (+0.08%)
ADSW : 32.34 (+0.03%)
PETX : 4.96 (+0.61%)
Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., Community Health Systems, Equity Bancshares, Inc., Ford Motor Company, Interface, Inc., Monotype Imaging Holdings, Inc., PetIQ, Inc., and Pinduoduo, Inc.

Aratana Therapeutics, Inc. (PETX)

PDD : 19.97 (-0.75%)
CYH : 2.24 (-3.86%)
EQBK : 24.56 (-1.01%)
F : 10.38 (-1.24%)
PETQ : 35.87 (+1.01%)
TILE : 15.00 (-1.12%)
PETX : 4.96 (+0.61%)
TYPE : 16.97 (-0.06%)
PETX, KEYW, and ZAYO SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

Rigrodsky & Long, P.A. announces that it is investigating:

ZAYO : 33.50 (+0.03%)
JEC : 85.66 (-0.10%)
KEYW : 11.23 (-0.18%)
PETX : 4.96 (+0.61%)
Aratana (PETX) Reports Q1 Loss, Tops Revenue Estimates

Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

PETX : 4.96 (+0.61%)
Aratana: 1Q Earnings Snapshot

LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Wednesday reported a loss of $6.8 million in its first quarter.

PETX : 4.96 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PETX with:

Business Summary

Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative...

See More

Key Turning Points

2nd Resistance Point 5.23
1st Resistance Point 5.08
Last Price 4.96
1st Support Level 4.79
2nd Support Level 4.65

See More

52-Week High 7.16
Fibonacci 61.8% 5.69
Fibonacci 50% 5.23
Last Price 4.96
Fibonacci 38.2% 4.77
52-Week Low 3.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar